Browse studies

Find your next paid study

58 recruiting studies matching your filters

Feasibility, Tolerance, and Fat Metabolism Pilot Study of a Structured Lipid Medical Food in Patients With Pancreatic Cancer

Patients with pancreatic cancer (pancreatic ductal adenocarcinoma (PDAC) and pancreatic neuroendocrine tumor (NET)) commonly experience fat malabsorption due t…

Pancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Neuroendocrine Tumor (NET)

Estimated

~$10 – $6,250

Children's Hospital of PhiladelphiaNCT07554560

Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)

Background: Neuroendocrine neoplasm (NENs)are rare cancers arising from the neuroendocrine cells and can affect almost any part of the body. They vary from lo…

Neuroendocrine TumorsCarcinoma, Neuroendocrine

Estimated

~$10 – $675

National Cancer Institute (NCI)NCT05237934

Investigating the Clinical Trial Journey and Engagement of Neuroendocrine Tumor Patients

Taking part in clinical trials usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect t…

Neuroendocrine Tumors

Estimated

~$10 – $1,050

Power Life Sciences Inc.NCT05967481

Observational

Randomized Controlled Trial of Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

Patients with digestive tract malignancy often experience severe and unremitting abdominal pain that negatively affects physical, emotional, and social functio…

Cancer PainVisceral PainGastrointestinal Neoplasms+76 more

Phase 2

A Phase II Study of Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

This is the first study to be done in a newly described class of neuroendocrine tumors known as well-differentiated grade 3 neuroendocrine tumors (WD G3 NET). …

Neuroendocrine TumorsWell-Differentiated Neuroendocrine CarcinomaHigh Grade Neuroendocrine Carcinoma, Any Site

Estimated

~$10 – $5,625

University of California, San FranciscoNCT05746208

Phase 3

Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy

This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ…

GEP-NETGastroenteropancreatic Neuroendocrine TumorGastroenteropancreatic Neuroendocrine Tumor Disease+4 more

Estimated

~$10 – $8,750

RayzeBio, Inc.NCT05477576

Phase 1

Biodistribution of 68Ga Pentixafor in Patients With Small Cell Lung Carcinoma (SCLC)

This is a first-in-human clinical trial evaluating the safety of an alpha-radiation treatment (Lead-212 labelled Pentixather) in patients who have been diagnos…

Carcinoid Tumor LungNeuroendocrine Tumor of the LungCarcinoma, Small-Cell Lung

Estimated

~$10 – $7,500

Yusuf MendaNCT05557708

Phase 1

A Phase I/II, Dose-escalation and Dose-optimization Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of MT-4561 in Patients With Various Advanced Solid Tumors and to Evaluate Effect of MT-4561 on Pharmacokinetics of Oral Midazolam

This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and effica…

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Esophageal Cancer+13 more

Estimated

~$10 – $8,750

Tanabe Pharma America, Inc.

Phase 1

A Pilot Study of 1-(2-[18f]Fluoroethyl)-L-Tryptophan PET/CT Imaging In Human Cancers

Imaging procedures such as 1-(2-\[18F\]FLUOROETHYL)-L-Tryptophan PET/CT in patients with cancers may help doctors assess a patient's response to treatment and …

Intracranial GliomaMetastatic Brain TumorBreast Cancer+2 more

Estimated

~$10 – $7,500

Barbara Ann Karmanos Cancer InstituteNCT05556473

Phase 1

Phase I Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid Tumors

This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the …

Metastatic Malignant Solid NeoplasmMetastatic MelanomaPathologic Stage IIIC Cutaneous Melanoma AJCC v8+14 more

177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry

The goal of this study is to learn if individualized dosimetry-based prescribing of Lutetium-177 DOTATATE (Lutathera, Novartis Pharmaceuticals) improves treatm…

Neuroendocrine TumorsNeuroendocrine Tumor Grade 1Neuroendocrine Tumor Grade 2

Estimated

~$10 – $6,250

University of IowaNCT06395402

Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine

The specific aim is of this study is to gain a better understanding of the patient characteristics, treatment responses, survival outcomes, and adverse events …

Neuroendocrine TumorsGastroenteropancreatic Neuroendocrine Tumor

Estimated

~$10 – $750

Methodist Health SystemNCT04090034